Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
| ▸ | POLG | P54098 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | AHCY | P23526 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5086067 | 0.94 | FGFR1 (0.44) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL5086360 | 0.93 | FGFR1 (0.43) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL5086061 | 0.92 | FGFR1 (0.44) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL5083589 | 0.90 | ADORA2A (0.44) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL5083657 | 0.87 | FGFR1 (0.36) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL5086440 | 0.86 | DNPH1 (0.35) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL5086346 | 0.84 | CCNB2 (0.36) | FGFR1 | |
| SCHEMBL5082361 | 0.82 | FGFR1 (0.47) | FGFR1SLC22A6FAPAHCYCYP3A4 | |
| SCHEMBL6316076 | 0.81 | FGFR1 (0.61) | FGFR1SLC22A6AHCYCYP3A4ENPP1 | |
| SCHEMBL5082379 | 0.81 | FGFR1 (0.33) | FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | FGFR1 3600/4885SLC22A6 1753/4885ABCB11 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.